355008-56-9

Upstream product

• 100-39-0 benzyl bromide 
• 497-19-8 sodium carbonate 
• 355008-55-8 methyl 3-(o-tolyl)isonicotinate 
• 188677-49-8 methyl 3-iodo-4-pyridinecarboxylate 
• 55279-30-6 methyl 3-aminoisonicotinate 
• 7579-20-6 3-Aminopyridine-4-carboxylic acid 
• 16419-60-6 2-Methylphenylboronic acid 

Downstream Products

• 355008-58-1 1-(1',1'-dimethylethoxycarbonyl)-3-(2-methylphenyl)-1,2,5,6-tetrahydroisonicotinic acid 
• 570397-03-4 4-(1-methoxycarbonyl-3-methylsulfanyl-propylcarbamoyl)-5-o-tolyl-3,6-dihydro-2H-pyridine-1-carboxylic acid 3-cyclohexyl-1-thiazol-5-yl-propyl ester 
• 355008-64-9 2-{[1-(benzyl-thiazol-5-ylmethyl-carbamoyl)-5-o-tolyl-1,2,3,6-tetrahydro-pyridine-4-carbonyl]-amino}-4-methylsulfanyl-butyric acid methyl ester 
• 355008-59-2 4-(1-methoxycarbonyl-3-methylsulfanyl-propylcarbamoyl)-5-o-tolyl-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Aryl tetrahydropyridine inhibitors of farnesyltransferase: Glycine, phenylalanine and histidine derivatives

Inhibitors of farnesyltransferase are effective against a variety of tumors in mouse models of cancer. Clinical trials to evaluate these agents in humans are ongoing. In our effort to develop new farnesyltransferase inhibitors, we have discovered a series of aryl tetrahydropyridines that incorporate substituted glycine, phenylalanine and histidine residues. The design, synthesis, SAR and biological properties of these compounds will be discussed.

Inhibitors of protein isoprenyl transferases

The present invention relates to novel compounds of Formula I which are useful in inhibiting protein isoprenyl transferases and the farnesylation or geranylgeranylation of the oncogene protein Ras and other related small g-proteins, and compositions containing such compounds and methods of using such compounds.